Team:Goettingen/Safety
From 2013.igem.org
(/* 5. If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise? (Consider the different categories of risks that are listed in parts a-d of the previous question.) Also, w) |
(→6. Does your project include any design features to address safety risks? (For example: kill switches, auxotrophic chassis, etc.) Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them.) |
||
Line 39: | Line 39: | ||
==6. Does your project include any design features to address safety risks? (For example: kill switches, auxotrophic chassis, etc.) Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them.== | ==6. Does your project include any design features to address safety risks? (For example: kill switches, auxotrophic chassis, etc.) Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them.== | ||
+ | <p>No. But as the most used model organism in molecular biology, the risk of E.coli is relatively low.</p> | ||
+ | |||
==7. What safety training have you received (or plan to receive in the future)? Provide a brief description, and a link to your institution’s safety training requirements, if available.== | ==7. What safety training have you received (or plan to receive in the future)? Provide a brief description, and a link to your institution’s safety training requirements, if available.== | ||
==8. Under what biosafety provisions will / do you work?== | ==8. Under what biosafety provisions will / do you work?== |
Revision as of 07:38, 27 August 2013